Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid MalignanciesDavid Olmos, Sarah P. Blagden, André T. Brunetto et al.|Clinical Cancer Research|2011Cited by 168
431 POSTER A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumorsSarah P. Blagden, Johann S. de Bono, David Olmos et al.|European Journal of Cancer Supplements|2008Cited by 4